

DAFTAR PUSTAKA

1. Kelly K. Hunt, MD, Geoffrey L. Robb, MD, Eric A. Strom, MD, and Naoto T. Ueno MP. Breast Cancer 2nd Edition Breast Cancer Series. Springer; 2008. 324 p.
2. Society AC. Breast Cancer Facts & Figures 2019-2020. Atlanta; 2019. 20-46 p.
3. Coughilin SS E DU. Breast Cancer As A Global Health Concern. *Cancer Epidemiol.* 2009;(33):315–8.
4. Kementrian Kesehatan RI. Hari Kanker Sedunia. 2018. 5-8 p.
5. Kementrian Kesehatan RI. Prevalensi Kanker Payudara di Indonesia. 2017. 5-10 p.
6. Weide, R., Feiten, S., Friesenhahn, V., Heymanns, J., Kleboth, K., Thomalla, J., van Roye, C. & Köppler H. Metastatic Breast Cancer: Prolongation of Survival in Routine Care is Restricted to Hormone-Receptor- and Her2-Positive Tumors. *Springerplus.* 2014;3:1–8.
7. Seedhom, A. E. & Kamal NN. Factors Affecting Survival of Women Diagnosed with Breast Cancer in El-Minia Governorate, Egypt. *Int J Prev Med.* 2011;(2):115–9.
8. Wulandari R. Peran Radioterapi Eksterna Adjuvan terhadap Penderita Kanker Payudara Stadium Lokal-Lanjut. 2012;3(1):5–8.
9. Yao Y, Chu Y, Xu B, Hu Q, Song Q. Risk Factors for Distant Metastasis of Patients with Primary Triple-Negative Breast Cancer. *Biosci Rep.* 2019;39(6):1–10.
10. Jamnasi J, Gondhowiardjo S, Djoerban Z, Siregar NC, Poetiray EDC, Tunggono AP. Faktor Risiko Terjadinya Metastasis Jauh Pada Pasien Kanker Payudara. 2016;7(2):55–9.
11. Aerden D, Massaad D, Kemp KV, Tussenbroek FV, Debing E KB. The Ankle Brachial Index and the Diabetic Foot: A Troublesome Marriage. *ELSEIVER.* 2011;770–1.
12. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M SD. The European Cancer Anaemia Survey (ECAS): A Large, Multinational, Prospective Survey Defining The Prevalence, Incidence, and Treatment of Anemia in Cancer Patients. *Eur J Cancer.* 2004;40(15):2293–2306.
13. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A TE. Anemia in Oncology Practice: Relation to Diseases and their Therapies. *Am J Clin Oncol.* 2002;25(4):371–379.

14. Lim J won. The impact of Comorbidity on The Relationship Between Life Stress and Health-Related Quality of Life for Chinese- and Korean-American Breast Cancer Survivors. *Ethn Heal.* 2018;23(1):16–32.
15. Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, et al. Associations of Breast Cancer Risk Prediction Tools with Tumor Characteristics and Metastasis. *J Clin Oncol.* 2016;34(3):251–8.
16. Jung SY, Rosenzweig M, Linkov F, Brufsky A, Weissfeld JL, Sereika SM, et al. Comorbidity as a Mediator of Survival Disparity Between Younger and Older Women Diagnosed With Metastatic Breast Cancer. 2011;186–8.
17. Kenar G. Prevalence , Etiology and Risk Factors of Anemia in Patients with Newly Diagnosed Cancer. 2020;2(4):15–25.
18. Maskarinec G, Sadakane A, Sugiyama H, Brenner A, Tatsukawa Y, Grant E. Type 2 diabetes, Obesity, and Breast Cancer Risk Among Japanese Women of The Atomic Bomb Survivor Cohort. *Cancer Epidemiol.* 2019;60:179–84.
19. Morrow M, Burstein HJ, Harris JR. *Malignant Tumors Of The Breast.* 2012. 1117–1156 p.
20. Tobias J H. *Cancer and Its Management.* Wiley-Blacwell London. 2010;223–49.
21. Masriadi. *Epidemiologi Penyakit Tidak Menular.* Jakarta Timur: CV.Trans Info Media; 2016. 48–52 p.
22. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating Tumor Cells At Each Follow-Up Time Point During Therapy Of Metastatic Breast Cancer Patients Predict Progression-Free And Overall Survival. *Clin Cancer Res.* 2006;12(14 Pt 1):4218–24.
23. Hayes, .D.F., Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Miller, M.C. E Al. Circulating Tumor Cells At Each Follow-Up Time Point During Therapy Of Metastatic Breast Cancer Patients Predict Progression-Free And Overall Survival. *Clin Cancer Res.* 2006;(12):4218–24.
24. Suyatno PE. *Bedah Onkologi Diagnosis dan Terapi.* Jakarta: Sagung Seto; 2014. 11–14 p.
25. The American Joint Committee on Cancer (AJCC). *Cancer Staging Manual.* 2010. 1-65 p.
26. Komite Penanggulangan Kanker Nasional. *Panduan Penatalaksanaan Kanker Payudara.* Kementerian Kesehat Republik Indones. 2015;1–45.
27. Balasubramanian P, Yang L, Lang JC, Jatana KR, Schuller D., Agrawal A ZMC. Confocal Images Of Circulating Tumor Cells Obtained Using A Methodology And Technology That Removes Normal Cells. *Mol Pharm.* 2009;6(5):1402–8.

28. Howlader NNA et al. SEER Cancer Statistics Review. Bethesda; 2011. 1975-2008 p.
29. Widikusumo A. Radiasi Paliatif Sebagai Tatalaksana Nyeri Pada Metastasis Tulang: Suatu Laporan Kasus Pada Kanker Palliative Radiation As Management of Pain in Bone Metastasis: Breast Cancer Case Study. 2016;2(2):16–9.
30. Bale R, Putzer D, Schullian P. Local Treatment of Breast Cancer Liver Metastasis. *Cancers (Basel)*. 2019;11(9):1–15.
31. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD. Effects of Surgical Excision on Survival of Patients with Stage IV Breast Cancer1. *J Surg Res*. 2010;161(1):83–8.
32. Silalahi L, Rahmi E, Sutarni S. Tumor Otak Metastasis Dari Kanker Payudara. *Berk Ilm Kedokt Duta Wacana*. 2018;3(1):48.
33. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD et al. The Urokinase System of Plasminogen Activation and Prognosis in Breast Cancer Patients. *Cancer Res*. 2000;60:43–636.
34. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A et al. Enhanced Benefit From adjuvant Chemotherapy in Breast Cancer Patients classified High-Risk According to Urokinase-Type plasminogen Activator (uPA) and Plasminogen Activator inhibitor Type 1. *Cancer Res*. 2001;62:22–4617.
35. Rostami, R., Mittal, S., Rostami P. Brain Metastasis in Breast Cancer : a Comprehensive Literature Review. *J Neurooncol*. 2016;22–7.
36. Dall GV BK. Estrogen Effects on The Mammary Gland in Early and Late Life and Breast Cancer Risk. *Front Oncol*. 2017;1–10.
37. Meier-Abt F B-AM. How Pregnancy at Early Age Protects Against Breast Cancer. *Trends Mol Med*. 2014;20(3):143–53.
38. Setiawan, V. W., Feigelson, H. S. & Henderson BE. Epidemiology and Risk Factor. *extbook of*. London: Tailor & Francis; 2006. 55–56 p.
39. Albert Simon TWM. Pengaruh Grading dan Lymphovascular Invasion Terhadap Metastasis Kelenjar Getah Bening Axilla Pada Kanker Payudara. *J Med*. 2016;5(6):1–7.
40. D. M. HER-2/neu and p53 Overexpression as Biomarkers of Breast Cancer Carcinoma in Women Age 30 Years and Younger. 2005. 53–54 p.
41. Porter GJR, Evans AJ, Pinder SE, James JJ, Cornford EC, Burrell HC, et al. Patterns of Metastatic Breast Carcinoma: Influence of Tumour Histological Grade. *Clin Radiol*. 2004;59(12):1094–8.
42. Koes Irianto. Epidemiologi Penyakit Menular Dan Tidak Menular Panduan

- Klinis. Bandung: Alfabeta CV; 2014. 312–314 p.
43. Sardjono C, Sandra F. Angiogenesis: Patofisiologi dan Aplikasi Klinis. *J Kedokt Maranatha*. 2009;8(2):174–87.
 44. Charlot M, Castro-Webb N, Bethea TN, Bertrand K, Boggs DA, Denis G V., et al. Diabetes and Breast Cancer Mortality in Black Women. *Cancer Causes Control*. 2017;28(1):61–7.
 45. Khaddour H, Elshimali YI, Dănciulescu-Miulescu R, Gradinaru D. Relationships Between Serum Expression of IGF-1 and Metabolic Syndrome Metrics in Syrian Women with Breast Cancer. *Rom J Diabetes Nutr Metab Dis*. 2020;26(4):435–43.
 46. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-analysis. *J Clin Oncol*. 2011;29(1):40–6.
 47. Vrachnis N, Iavazzo C, Iliodromiti Z, Sifakis S, Alexandrou A, Siristatidis C, et al. Diabetes Mellitus and Gynecologic Cancer: Molecular Mechanisms, Epidemiological, Clinical and Prognostic Perspectives. *Arch Gynecol Obstet*. 2016;293(2):239–46.
 48. Soelistijo S, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe2 Di Indonesia 2015. *Perkeni*. 2015. 82–85 p.
 49. Kementerian Kesehatan Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riskesdas 2018. 2019. 8-20 p.
 50. Behrman RE, Kliegman RM, Jenson HB SB. Iron Deficiency Anemia. Philadelphia: Saunders; 2007. 1469–71 p.
 51. Dor Y, Porat R KE. Vascular Endothelial Grow Factor and Vascular Adjustment to Pertubations in Oxygen Homeostatis. *Am J Physiology-cell*. 2001;6(280):1367–74.
 52. Takabatake D, Oishi K. Microangiopathic Hemolytic Anemia Associated with Metastatic Breast Cancer: Case Report and Literature Review. *Springerplus*. 2016;5(1):1–6.
 53. Kementerian Kesehatan RI. Pedomam Interaktif Data Klinik. 2011. 10-93 p.
 54. Rahayu U W. Mengenal dan Mencegah Penyakit Diabetes, Hipertensi, Jantung dan Stroke Untuk Hidup Lebih Berkualitas. Yogyakarta: Media Ilmu; 2015. 12–15 p.
 55. Brown NS BR. Hypoxia and Oxidative Stress In Breast Cancer Oxidative Stress : Its Effects On The Growth, Metastatic Potential and Response to Therapy of Breast Cancer. *Breast Cancer Res*. 2001;3(5):323–7.
 56. American College of Cardiology. Guideline For the Prevention, Detection,

- Evaluation and Management of High Blood Pressure in Adult. 2017.
57. Kementerian Kesehatan RI. Epidemi Obesitas. 2017. 8-12 p.
 58. Irmawartini N. Metode Penelitian. 7th ed. Kementerian kesehatan RI; 2017. 55–57 p.
 59. National Cancer Institute Surveillance, E., and End Results Program Cancer Stat Fact: Female Breast Cancer. 2016. 5-20 p.
 60. William L. Tumor-Related Prognostic Factors for Breast Cancer. *CACancer JCI*; 2002. 28–51 p.
 61. Djamil. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara antara Pasien Kanker Payudara. *J Kesehat Andalas*. 2015;38:208–17.
 62. Zhao s, Zhang M, Tang D, shi Q, zu S. High Expression of CD147 and MMP-9 is Correlated With Poor Prognosis of Triple-Negative Breast Cancer (TNBC) Patients. *Med Oncol*. 2013;30(335):1–8.
 63. Niasari M, Hoesin F, Anatomik DP, Kedokteran F, Airlangga U. Analisis Ekspresi Vascular Endothelial Growth Factor (VEGF) dan Kepadatan Mikrovaskuler pada Invasive Breast Carcinoma of No Special Type Grade 3 dengan Metastasis Kelenjar Getah Bening Aksila. 2016;25(1):67–72.
 64. Laitakari J, Nayha V SF. Size, Shape, Structure, and Direction of Angiogenesis in Laryngeal Tumour Development. *J clin Pathol*. 2004;4(57):394–401.
 65. Timar J, Csuka O, Orosz Z, Jeney A KL. Molecular Pathology of Tumor Metastasis. *Pathol Oncol Res*. 2002;3(7):217–30.
 66. Tjaka W. Panduan Penatalaksanaan Kanker Solid: Panduan Penatalaksanaan Kanker Payudara. *PERABOI*; 2010. 17–47 p.
 67. Nisa A, Bhurgi Y, Raza F KN. Comparison of ER,PR & HER-2/neu (C-erbB2) Reactivity Pattern with Histopatologic Grade, Tumor Size and Lymph Node Status in Breast Cancer. *Asian Pacific J Cancer Prev*. 2008;9:553–6.
 68. Raniah Baswedan, Heru purwanto AR. Profil Pemeriksaan Histopatologi Karsinoma Payudara di Departemen/SMF Patologi Anatomi RSUD DR Soetomo Surabaya Periode 2010-2013. *Patol Soetomo, Rsud Periode, Surabaya*. 2013;3:24–9.
 69. Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S TH. Histopathological Criteria for Assessment of Therapeutic Response in Breast Cancer. *Breast cancer*. 2008;15(1):5–7.
 70. Katherina Z, James A.C , Francisco J.D , Michela A , Kevin S.H JIJ et. al. Breast Cancer in Women ≤ 40 versus 50 To 60 Years : Increasing Size and Stage Disparity Compared With Older Women Over Time. *Ann Surg Oncol*.

- 2006;3(3):1–6.
71. Robbins & Cotran. Payudara. 6th ed. Buku Kedokteran EGC; 2005. 1141–74 p.
 72. Engstrom MJ, Opdahl S HA. Histopatological Grade and Survival in a Historic Cohort of Breast Cancer Patients. *Breast Cancer Res Treat.* 2013;140 (3):463–373.
 73. Uzma Raza, Mahay Rookh Asif, Asif Bin Rehman AS. Hyperlipidemia and Hyper Glycaemia in Breast Cancer Patients is Related to Disease Stage. *pjms.* 2018;34(1):209–14.
 74. Freig, Barry W. *The MD Anderson Surgical Oncology Handbook.* Philadelphia: MD anderson cancer center; 2011. 8–26 p.
 75. Ward WD. Pathophysiology of Insulin Secretion in on Insulin Dependent Diabetes Mellitus. *New York Diabetes Care.* 2002;4(1):491–502.
 76. Big pan et al. HDL of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer Metastasis. *Am Assoc cancer Res.* 2012;18:1246–56.
 77. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Deer RL et. al. Long-team all-cause Mortality in Cancer Patients with Preexisting Diabetes Mellitus; A Systematic Review and Meta-analysis. *JAMA.* 2008;300:2754–64.
 78. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR hUX J. The Impact of Diabetes on Survival Following Breast Cancer. *Breast Cancer Res.* 2008;109:389–95.
 79. Behrman RE, Kliegman RM JHS. *Iron Deficiency Anemia.* Philadelphia: Saunders; 2001. 1469–71 p.
 80. Aldoss IT, Wilson S SP. *Chemotherapy-Induced Anemia.* 2008. 24–26 p.
 81. Silva E. Kim H. Thrombocytopenia: Focus on Platelet Apoptosis. *Chem Biol Interact.* 2018;284:1–11.
 82. Lyman G GJ. Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment. *Oncol J.* 2006;20(8):1517–25.
 83. zhang H. HIF-1 Inhibit Mitochondrial Biogenesis and Cellular Respiration on VHL Deficient Renal Cell Ca by Depression of c-myc Activity. *Cancer Cell.* 2007;2:20–407.
 84. Samenza GL. Hypoxia-Induced Factor 1 and Cancer Pathogenesis. *USA IUBMB Life.* 2008;7–591.
 85. Safarudin, Nurhayati A, Prihartono WG. Pengaruh Indeks Massa Tubuh terhadap Disease-Free Survival Lima Tahun Pasien Kanker Payudara di

- Rumah Sakit Kanker “Dhamais” Jakarta. *Indones J Cancer*. 2016;10(1):27–18.
86. Caldefie-Chezet F, Damez M, de Latour M D. Leptin : A Proloferative Factor for Breast Cancer : Study on Human Ductal Carcinoma. *Biochem Biophys Res Commun*. 2005;334:41–737.
 87. Neels JG, Thinnest LD. Angiogenesis in an in Vivo Model of Adipose Tissue Development. *Faseb*. 2004;18:5–983.
 88. Silha JV, Kresk M, Sucharda P ML. Angiogenesis Factors are Elevated in Overweight and Obese Individuals. *Int J Obes*. 2005;29(13):8–14.
 89. Yin N, Wang D, Zhang H et. a. Molecular Mechanisms Involved in the Growth Simulation of Breast Cancer Cell by Leptin. *Cancer Res*. 2004;64(58):5–70.
 90. Putu N, Rakasiwi D, Setiawan GB, Ngr IG, Aryana W. Karakteristik Kanker Payudara dengan Metastasis Tulang Tahun 2015-2017 di RSUP Sanglah Denpasar. *J Med udayana*. 2020;9(1):17–22.
 91. Cetin, Karynsa et al. Survival in Patients with Breast Cancer with Bone Metastasis: a Danish Population-Based Cohort Study on the Prognosis and Length of the Bone Metastasis-free Interval. *BMJ*. 2015;5(4):702.
 92. Society AC. *Breast Cancer Facts & Figures 2015-2016*. Atlanta; 2015.5-6p.
 93. Smith CL, Santeb RJ, Kommn B MS. Breast-Related Effects of Selective Estrogen Reseptor Modulators and Tissue-Selective Estrogen Complexes. *Breast Cancer Res*. 2014;16(5):212–6.
 94. Ambrosone CB, Zirpoli G, Hong CC et. a. Important Role of Manarce in Development of Estrogen Reseptor Negative Breast Cancer in African American Women. *JNCI Narl Cancer Inst*. 2015;107(9):1–10.
 95. Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, et al. Breast Cancer Risk After Recent Childbirth A Pooled Analysis of 15 Prospective Studies. *Ann Intern Med*. 2018;3(5):1–10.
 96. Schedin P. Pregnancy-Associated Breast Cancer and Metastasis. 2006;6:281–91.